Document › Details

Evotec AG. (1/2/13). "Press Release: Evotec and Apeiron Biologics Announce Collaboration on Cancer Immunotherapy". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
  Organisation 2 Apeiron Biologics AG
  Group Apeiron (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 drug development
Index term Index term Apeiron–Evotec: cancer immunotherapy, 201301– collab €na development of lead compounds
Persons Person Polywka, Mario (Evotec 201201–201812 COO RETIRED 12/18)
  Person 2 Loibner, Hans (Apeiron Biologics 200810–201807 CEO RETIRED 7/18 continues as senior advisor)
     


Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration while Evotec will be responsible for medicinal chemistry as well as chemical proteomics. The collaboration is based on the successful outcome of a phenotypic high throughput screen previously commissioned by Apeiron Biologics to Evotec.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We look forward to continue working with Apeiron on this important project. The collaboration highlights the strength of Evotec's phenotypic screening capabilities to identify novel mechanisms and hits in important therapeutic areas.'

Dr Hans Loibner, Chief Executive Officer of Apeiron Biologics, added: 'We were excited about the outcome of the primary screen and look forward to refining the hit compounds in this collaboration applying our immunological know-how. There is no doubt that immunomodulatory compounds like these carry huge therapeutic and commercial potential.'

No financial details are disclosed.


ABOUT APEIRON Biologics AG

Apeiron is a mostly privately financed biotech company in Vienna that develops immunological/biological therapies against cancer. Its portfolio consists of five clinical projects (lead in phase III) as well as some preclinical approaches. The most advanced project APN311 is an antibody to treat the pediatric cancer neuroblastoma. The immunocytokine hu14.18-IL2 (APN301) is being developed clinically in neuroblastoma as well as in melanoma. Moreover, recombinant human superoxide dismutase is in clinical development, notably in a topical liposomal formulation (APN201) as a potent anti-inflammatory tissue-protective biologic. Two complementary approaches are pursued (APN401, APN411) that stimulate immune cells in a novel way to treat cancer more effectively. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, previously APN01) was licensed out to GlaxoSmithKline in early 2010 and is currently investigated in a phase II trial in patients suffering from acute lung injury. Apeiron started operations in 2006 and has 23 employees as of today.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

   
Record changed: 2017-04-02

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px




» top